| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 151,371 | 144,711 | ||
| Marketable securities | 129,789 | 377,885 | ||
| Accounts receivable, net | 171,254 | 140,831 | ||
| Inventories, net | 79,399 | 44,023 | ||
| Prepaid expenses and other current assets | 62,078 | 31,416 | ||
| Total current assets | 593,891 | 738,866 | ||
| Restricted cash | 1,450 | - | ||
| Property and equipment, net | 10,627 | 11,069 | ||
| Intangible assets, net | 623,481 | 481,307 | ||
| Goodwill | 119,080 | 117,019 | ||
| Deferred income tax assets, net | 8,793 | 6,181 | ||
| Other assets | 62,432 | 27,963 | ||
| Total assets | 1,419,754 | 1,382,405 | ||
| Accounts payable and accrued liabilities | 108,613 | 77,739 | ||
| Accrued product returns and rebates | 184,459 | 180,916 | ||
| Contingent consideration, current portion | 11,235 | 0 | ||
| Other current liabilities | 26,322 | 27,705 | ||
| Total current liabilities | 330,629 | 286,360 | ||
| Contingent consideration, long-term | 213 | - | ||
| Operating lease liabilities, long-term | 31,422 | 24,383 | ||
| Deferred income tax liabilities, net | 0 | 0 | ||
| Other liabilities | 7,823 | 7,762 | ||
| Total liabilities | 370,087 | 318,505 | ||
| Common stock, 0.001 par value 130,000,000 shares authorized 57,119,153 and 55,743,095 shares issued and outstanding as of september 30, 2025 and december31, 2024, respectively | 57 | 56 | ||
| Additional paid-in capital | 527,700 | 496,946 | ||
| Accumulated other comprehensive loss, net of tax | -71 | -200 | ||
| Retained earnings | 521,981 | 567,098 | ||
| Total stockholders' equity | 1,049,667 | 1,063,900 | ||
| Total liabilities and stockholders' equity | 1,419,754 | 1,382,405 | ||
SUPERNUS PHARMACEUTICALS, INC. (SUPN)
SUPERNUS PHARMACEUTICALS, INC. (SUPN)